Polomar Health Services, Inc. SEC 10-Q Report

Polomar Health Services, Inc., a licensed retail compounding pharmacy operating under the name Polomar Specialty Pharmacy, has released its Form 10-Q report for the third quarter of 2025. The report provides a comprehensive overview of the company's financial performance and operational developments, reflecting the ongoing transition to an online business model and strategic initiatives aimed at expanding its market reach.

Financial Highlights

• Revenue: $10,011,000. The decrease in revenues over the previous accounting period was primarily due to the company's post-merger transition to an online business model.
• Gross Profit: $7,013,000. This reflects a decrease compared to the previous period, indicating challenges in maintaining profit margins.
• Loss from operations: $(978,742). Operating expenses increased significantly due to higher legal, professional, and accounting fees, as well as stock-based compensation.
• Net loss: $(1,062,418). The net loss increased compared to the previous year, driven by higher operating expenses and insufficient revenue generation.
• Net loss per common share: basic and diluted: $(0.04). This reflects the impact of the increased net loss on shareholders.

Business Highlights

• Business Model and Operations: Polomar Health Services, Inc. operates Polomar Specialty Pharmacy, a licensed retail compounding pharmacy in Florida, authorized to dispense injectable and sterile compounds. The company is expanding its reach to fulfill prescriptions in 28 states and is seeking further approvals to cover a majority of U.S. states by the end of 2025.
• New Product Launches: The company plans to launch SlimRx, an online platform for weight loss medications, in early Q4 2025. This platform will connect patients with healthcare providers to prescribe medications like semaglutide compounded with vitamin B-12.
• Future Product Launches: Polomar anticipates launching PoloMeds in Q4 2025 to fulfill prescriptions for diabetes medications and other specialized treatments, leveraging its license agreement with Pinata, Inc.
• Strategic Partnerships: A Product Fulfillment and Distribution Agreement with ForHumanity, Inc. allows exclusive marketing of inhalable sildenafil and sumatriptan, with Polomar responsible for fulfilling prescriptions.
• Corporate Developments: The company underwent a reverse recapitalization with Polomar as the accounting acquirer, ceasing commercialization of its pre-existing business.
• Future Outlook: Polomar is actively seeking to expand its prescription fulfillment services for third-party telehealth platforms, clinics, and hospitals, expecting steady growth in this wholesale segment over the next 12 to 18 months.

SEC Filing: Polomar Health Services, Inc. [ TRFE ] - 10-Q - Aug. 19, 2025